Escalation: Step the dose up every few weeks e.g
Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms
L-NAME initially caused all vessels to disappear more rapidly and L-arginine increased the number of vessels (L-NAME R, L-arginine R, opposite ), but both induced larger pale areas (L-NAME R, L-arginine R, parallel ), all as NO-specific (NO-related) effects, as L-NAME and L-arginine regularly attenuated or antagonized each others responses (L-NAME R, L-arginine R, opposite , specific
Contribution of semen to early embryo development: fertilization and beyond
A: Sterile water with 0.9% benzyl alcohol for peptide reconstitution, injectable medication dilution, and research applications
